Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00235222

Recruitment Status : Unknown

Verified October 2005 by Groupe Hospitalier Pitie-Salpetriere.
Recruitment status was: Active, not recruiting

First Posted : October 10, 2005

Last Update Posted : October 25, 2005

Sponsor:

Collaborator:

Bristol-Myers Squibb

Information provided by:

Groupe Hospitalier Pitie-Salpetriere

Study Description

Brief Summary:

Lipodystrophie, peripheral neuropathy and mitochondrial toxicity has been associated to stavudine at standard doses The aim of this study is to evaluate the efficacy of reduced doses of stavudine (30 mg b.i.d.) in HIV patients with controlled viral load and body weight > 60 kg, receiving an antiretroviral therapy containing stavudine 40 mg b.i.d.

Condition or disease	Intervention/treatment	Phase
HIV	Drug: stavudine	Phase 4

Detailed Description:

Stavudine is a nucleoside inhibitor larged used in HIV treatments and has been associated to mithocondrial toxicity. As it is still largely used in developping countries,the evaluation of reducing dose is of importance.

A single-arm open pilot 48 weeks study to evaluate the capacity of a switch from d4T 40 mg to 30 mg bid in patients with body weight > 60kg to maintain full viral load suppression. Clinical and biological evaluations were carried out at baseline, W24 and W48. Primary end-point is viral load suppression (<400 coies/ml) at W24.

Secondary end-points are : Evolution of CD4 count at W24 and W48, neurological examination at Baseline, W24 and W48, metabolic parameters and stavudine PK at W24.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Enrollment :	57 participants
Allocation:	Non-Randomized
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY
Study Start Date :	June 2004
Study Completion Date :	March 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Drug Information available for: Stavudine

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :

Proportion of patients with viral load < 400 copies/ml at week S24

Secondary Outcome Measures :

Clinical and biological safety of the reduced doses of stavudine at week 24. Percentage of patients with viral load < 400 copies/ml at week 48, evolution of Cd4 count from baseline to W24 and 48. Evolution of metabolic parameters from baseline to W24 and

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

HIV patients
Patients with an antiretroviral treatment containing stavudine at standard doses (40mg BID) for at least 3 months
Patients with viral load < 400 copies/ml for at least 3 months

Exclusion Criteria:

Patients receiving an antiretroviral therapy containing stavudine at 30mg BID
Current Opportunistic Infection
Current chemotherapy or under cytokines treatment (PEG, INF, IL2)
Pregnant or feeding Women

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00235222

Locations

Layout table for location information

France
Service de Maladies Infectieuses Hôpital Pitié-Salpêtrière
Paris, France, 75013

Sponsors and Collaborators

Groupe Hospitalier Pitie-Salpetriere

Bristol-Myers Squibb

Investigators

Layout table for investigator information

Study Chair:	Manuela BONMARCHAND, MD	Service de médecine Interne Hôpital Pitié Salpêtrière
Study Chair:	Hocine AIT-MOHAND, MD	Service de Maladies Infectieuses Hôpital Pitié Salpêtrière

More Information

Layout table for additonal information

ClinicalTrials.gov Identifier:	NCT00235222 History of Changes
Other Study ID Numbers:	CREPATS 05-01-PHOENIX
First Posted:	October 10, 2005 Key Record Dates
Last Update Posted:	October 25, 2005
Last Verified:	October 2005

Keywords provided by Groupe Hospitalier Pitie-Salpetriere:


Stavudine Reduced dose of stavudine Viral load Peripheral neuropathy Treatment Experienced

Additional relevant MeSH terms:

Layout table for MeSH terms

Stavudine Antimetabolites Molecular Mechanisms of Pharmacological Action Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors	Enzyme Inhibitors Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Anti-HIV Agents

To Top